Jeverson and coworkers found that Corilagin decreased p-cdc2 (Tyr15) and cyclin B1 levels in ovarian cancer cells (Hey and SKOv3ip), which may be a molecular mechanism associated with cell cycle arrest45. Here, CDK1 is linked to ovarian carcinoma.